Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry.1992;49:761-768.
Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psychiatry.1992;49:831-834.
Greenberg PE, Stiglin LE, Finkelstein SN.
et al. The economic burden of depression in 1990. J Clin Psychiatry.1993;54:405-418.
Wells KB, Stewart A, Hays RD.
et al. The functioning and well-being of depressed patients: results from
the Medical Outcomes Study. JAMA.1989;262:914-919.
Von Korff M, Ormel J, Katon W, Lin E. Disability and depression among high utilizers of health care: a longitudinal
analysis. Arch Gen Psychiatry.1992;49:91-100.
Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors:
Global Burden of Disease Study. Lancet.1997;349:1436-1442.
Robins L, Regier DA. Psychiatric Disorder in America. New York, NY: Free Press; 1991.
Kessler RC, McGonagle KA, Zhao S.
et al. Lifetime and 12-month prevalence of DSM-III-R
psychiatric disorders in the United States: results from the National Comorbidity
Survey. Arch Gen Psychiatry.1994;51:8-19.
Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of
major depression: a prospective study. Am J Psychiatry.1992;149:795-800.
Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes. Am J Psychiatry.1986;143:18-23.
Montgomery SA, Dufour H, Brion S.
et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry.1988;153(suppl 3):69-76.
Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry.1992;160:217-222.
US Department of Health and Human Services. Depression Guideline Panel, Depression in Primary
Care, Treatment of Major Depression. Vol 2. Washington, DC: Agency for Health Care Policy and Research;
NIMH/NIH Consensus Development Conference Statement. Mood disorders. Am J Psychiatry.1985;142:469-476.
Coppen A, Mendelwicz J, Kielholz P. Pharmacotherapy of Depressive Disorders: A Consensus
Statement. Geneva, Switzerland: World Health Organization; 1986.
Prien RF, Kupfer DJ, Mansky PA.
et al. Drug therapy in the prevention of recurrences in unipolar and bipolar
affective disorders. Arch Gen Psychiatry.1984;41:1096-1104.
Frank E, Kupfer DJ, Perel JM.
et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry.1990;47:1093-1099.
Robinson DS, Lerfald SC, Bennett B.
et al. Continuation and maintenance treatment of major depression with the
monoamine oxidase inhibitor phenelzine. Psychopharmacol Bull.1991;27:31-39.
Not Available. Not Available Prescription data for 1997, Ambler, Pa: IMS America.
Keller MB, Rush AJ, Thase ME.
et al. Evaluating optimal treatment strategies in chronic depression. J Clin Psychiatry.1998;59:560-568.
Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry.1960;23:56-62.
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry.1979;134:382-389.
Mason BJ, Kocsis JH, Leon AC.
et al. Assessment of symptoms and change in dysthymic disorder. In: Kocsis JH, Klein DN, eds. Diagnosis and Treatment
of Chronic Depression. New York, NY: Guilford Press; 1995:73-88.
Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health,US Dept of Health,
Education, and Welfare; 1976:76-338.
Beck AT, Epstein N, Brown G, Steer RA. Psychometric properties of the Beck Depression Inventory: twenty-five
years later. Clin Psychol Rev.1988;8:77-100.
Keller MB, Lavori PW, Friedman B.
et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method
for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry.1987;44:540-548.
Kupfer DJ, Frank E, Perel JM.
et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry.1992;49:769-773.
Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic
agents. Drug Saf.1994;10:103-114.
Littrell J. Relationship between time since reuptake-blocker antidepressant discontinuation
and relapse. Exp Clin Psychopharmacol.1994;2:82-94.